Patents Represented by Attorney Roy D. Meredith
  • Patent number: 5187074
    Abstract: A novel dipeptide isostere is the biotransformed product after incubation with a culture of Streptomyces. It inhibits HIV protease, and is useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as a compound, pharmaceutically acceptable salt, pharmaceutical composition ingredient, whether or not as a prodrug or as a combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: February 20, 1992
    Date of Patent: February 16, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Laszlo R. Treiber, Russell B. Lingham, Byron H. Arison, Lawrence F. Colwell, Jr., Georgette Dezeny, Nancy E. Kohl
  • Patent number: 5185251
    Abstract: Fermentation of the microorganism Actinoplanacete sp. (MA6559), ATTC No. 53771, in the presence of the HIV reverse transcriptase inhibitor ##STR1## yields 3-[2-(benzoxazol-2-yl)ethyl]-5-(1-hydroxyethyl)-6-methyl-2(1H)-pyridinone and 3-[2-(benzoxazol-2-yl)ethyl]-5-ethyl-6-hydroxymethyl-2(1H)-pyridinone, both of which are useful in the prevention or treatment of infection by HIV and the treatment of AIDS.
    Type: Grant
    Filed: June 7, 1991
    Date of Patent: February 9, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Shieh-Shung T. Chen, George Doss
  • Patent number: 5169769
    Abstract: Incubation of ##STR1## with a preparation from mammalian organ yields as biotransformation products the 6-hydroxymethyl and 5-(1-hydroxy)ethyl anologs. These products are useful in the prevention or treatment of infection by HIV and the treatment of AIDS.
    Type: Grant
    Filed: June 7, 1991
    Date of Patent: December 8, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Suresh K. Balani, Byron H. Arison, Harri G. Ramjit, Anthony D. Theoharides, Laura R. Kauffman
  • Patent number: 5169952
    Abstract: An efficient process for stereoselective preparation of a medicinally significant hydroxyamide compound of structural formula: ##STR1## comprises the addition of metalated amide enolates to chiral .alpha.-amino metalated epoxides. The hydroxyamide reaction products are useful as inhibitors of the HIV protease or of renin, or as intermediates in the preparation of inhibitors of the HIV protease or renin.
    Type: Grant
    Filed: July 2, 1991
    Date of Patent: December 8, 1992
    Assignee: Merck & Co., Inc.
    Inventors: David Askin, Ralph Volante, Michael Wallace, Ichiro Shinkai
  • Patent number: 5137876
    Abstract: The compound having the formula: ##STR1## has antiviral activity, specifically in the prevention or treatment of infection by retroviruses, including HIV, and immunosuppressive activity, either as a compound, pharmaceutically acceptable salt, or a pharmaceutical composition ingredient, whether or not in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing or treating viral infections and modulating immune responses in vivo are also described.
    Type: Grant
    Filed: October 12, 1990
    Date of Patent: August 11, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Malcolm MacCoss, Laura C. Meurer, Richard L. Tolman
  • Patent number: 5130247
    Abstract: The present invention relates to recombinant fusion polypeptides of HIV envelope and HBsAg, suitable as vaccines against AIDS and/or ARC and hepatitis, as well as immunogens for inducting antibodies for passive protection or treatment of AIDS and/or ARC.
    Type: Grant
    Filed: September 19, 1989
    Date of Patent: July 14, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Peter J. Kniskern, Arpi Hagopian, Pamela Burke
  • Patent number: 5130248
    Abstract: The present invention relates to recombinant fusion polypeptides of HIV envelope and HBsAg, suitable as vaccines against AIDS and/or ARC and hepatitis, as well as immunogens for inducing antibodies for passive protection or treatment of AIDS and/or ARC.
    Type: Grant
    Filed: September 19, 1989
    Date of Patent: July 14, 1992
    Assignee: Merck & Co., Inc.
    Inventors: Peter J. Kniskern, Arpi Hagopian, Pamela Burke
  • Patent number: 5124327
    Abstract: Novel indole compounds inhibit HIV reverse transcriptase, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, either as compounds or pharmaceutical composition ingredients, whether or not in combination with other antivirals, anti-infectives, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.
    Type: Grant
    Filed: September 6, 1991
    Date of Patent: June 23, 1992
    Assignee: Merck & Co., Inc.
    Inventors: William J. Greenlee, P. C. Srinivasan
  • Patent number: 5026828
    Abstract: Recombinant hepatitis B antigen bound to yeast membranes in yeast expression systems is rapidly purified by subjecting the membrane bound protein to agents that release undesired proteins, followed by agents that release the recombinant hepatitis B antigen.
    Type: Grant
    Filed: December 1, 1988
    Date of Patent: June 25, 1991
    Assignee: Merck & Co., Inc.
    Inventor: Shigeko Yamazaki
  • Patent number: 5024836
    Abstract: The invention comprises a lyophilized live herpes virus vaccine that comprises from about 0.5% to about 8% moisture.
    Type: Grant
    Filed: October 19, 1989
    Date of Patent: June 18, 1991
    Assignee: Merck & Co., Inc.
    Inventors: William J. McAleer, Robert Z. Maigetter, Henry Z. Markus
  • Patent number: 5013650
    Abstract: A galactose-regulated yeast strain expresses a desired protein in improved yield by growing the transformed yeast cells in culture in fed-batch mode and replacing the culture medium with fresh medium before adding the galactose to induce expression of the foreign protein.
    Type: Grant
    Filed: August 25, 1988
    Date of Patent: May 7, 1991
    Assignee: Merck & Co., Inc.
    Inventor: Christine E. Carty
  • Patent number: 5011915
    Abstract: Methods of purifying recombinant surface antigen of hepatitis B virus are disclosed. In one protocol, purification is achieved by selective extraction of the antigen from yeast membranes, followed by solubilization with urea and dithiothreitol.
    Type: Grant
    Filed: October 26, 1987
    Date of Patent: April 30, 1991
    Assignee: Merck & Co., Inc.
    Inventor: Shigeko Yamazaki
  • Patent number: 5004741
    Abstract: Methods of antagonizing gastrin and/or cholecystokinin (CCK) with benzodiazepine analogs are disclosed, as well as related pharmaceutical compositions, which are useful in treating disorders of the gastrointestinal tract, central nervous system, and of the appetite.
    Type: Grant
    Filed: November 9, 1988
    Date of Patent: April 2, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Ben E. Evans, Mark G. Bock, Roger M. Freidinger
  • Patent number: 4999436
    Abstract: Aryl substituted thiophenes 3-ols, its dihydro derivatives, 1-oxide and 1,1-dioxide analogs, as well as aryl substituted furans, are 5-lipoxygenase inhibitors useful in the treatment of inflammation and other leukotriene-mediated diseases.
    Type: Grant
    Filed: August 22, 1989
    Date of Patent: March 12, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Bruce E. Witzel, Debra L. Allison, Charles G. Caldwell, Kathleen Rupprecht
  • Patent number: 4880938
    Abstract: Analogs of glutamic acid and related amino acids and pharmaceutically-acceptable salts thereof which antagonize the function of cholecystokinins and gastrin disease states in animals and compositions for and methods of preventing or treating disorders of the gastrointestinal, central nervous and appetite regulatory systems of mammals, especially of humans.
    Type: Grant
    Filed: June 16, 1986
    Date of Patent: November 14, 1989
    Assignee: Merck & Co., Inc.
    Inventor: Roger M. Freidinger
  • Patent number: 4859771
    Abstract: An economical, one-pot process for resolution-racemization of primary amines with .alpha.-hydrogens via selective crystallization of diastereomeric chiral sulfonic acid salts and the subsequent in situ racemization of the other enantiomer by the catalytic addition of aromatic aldehydes, and a key process intermediate thereof.
    Type: Grant
    Filed: January 19, 1989
    Date of Patent: August 22, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Paul J. Reider, Edward J. J. Grabowski
  • Patent number: 4853415
    Abstract: 2-(Substituted sulfamyl) derivatives of 4-nitrobenzamide are disclosed as agents that increase the sensitivity of hypoxic cancer cells to x-rays and .gamma.-radiation. Methods of preparing such compounds, protocols for administering them to human patients and animals, and pharmaceutical compositions containing them are also disclosed.
    Type: Grant
    Filed: December 5, 1988
    Date of Patent: August 1, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Edward L. Engelhardt, Walfred S. Saari
  • Patent number: 4847248
    Abstract: Aromatic 1,4-benzodiazepines with fused 5- or 6-membered heterocyclic rings which are antagonists of cholecystokinins and/or gastrin, and are useful in the treatment or prevention of CCK-related and/or gastrin-related disorders of the gastrointestinal, central nervous and appetite regulatory systems; compositions comprising these compounds; and methods of treatment employing these compounds.
    Type: Grant
    Filed: January 6, 1988
    Date of Patent: July 11, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Roger M. Freidinger, Ben E. Evans, Mark G. Bock
  • Patent number: 4847294
    Abstract: Derivatives of 2-(Substituted sulfamyl) 6-nitrobenzoic acids are disclosed, wherein at least one of the sulfamyl substituents is selected from amino-(lower alkyl), (lower alkyl)-amino-(lower alkyl), or di(lower alkyl)-amino-(lower alkyl), hydrogen, lower alkyl, hydroxy-(lower alkyl), allyl, or when taken together with the nitrogen of the sulfamyl moiety, form a heterocyclic ring. These compounds have activity in increasing the sensitivity of hypoxic tumor cells to therapeutic radiation. Also disclosed are methods of preparing such compounds and pharmaceutical compositions including such compounds.
    Type: Grant
    Filed: June 1, 1987
    Date of Patent: July 11, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Edward L. Engelhardt, Walfred S. Saari
  • Patent number: 4845284
    Abstract: This application discloses new substituted 3-nitrobenzensulfonamides which are useful in enhancing the effect of therapeutic radiation. It also discloses pharmaceutical composition of such compounds, and a method of treatment of patients by administering an effective amount of a substituted 3-nitrobenzenesulfonamide to a patient in need of radiation therapy.
    Type: Grant
    Filed: December 3, 1986
    Date of Patent: July 4, 1989
    Assignee: Merck & Co., Inc.
    Inventors: Edward L. Engelhardt, Walfred S. Saari